68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in staging of high-risk prostate cancer patients: Preliminary analysis on 13 patients
Paola Scifo1, Paola Mapelli1,2, Samuele Ghezzo2, Ana Maria Samanes Gajate1, Erik Preza1, Giorgio Brembilla2,3, Vito Cucchiara2,4, Naghia Ahmed5, Carolina Bezzi1,2, Annarita Savi1, Ilaria Neri1, Ettore Di Gaeta3, Luigi Gianolli1, Massimo Freschi5, Alberto Briganti2,4, Francesco De Cobelli2,3, and Maria Picchio1,2
1Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy, 2Vita-Salute San Raffaele University, Milan, Italy, 3Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy, 4Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy, 5Department of Pathology IRCCS San Raffaele Scientific Institute, Milan, Italy
The use of PET/MRI scanners is an innovative approach to stage prostate cancer (PCa) and the combined use of both 68Ga-PSMA and 68Ga-DOTA-RM2 radiotracers can improve disease staging by providing different metabolic aspects of the tumour. In the present study, 13 patients with high-risk PCa undergoing 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI before radical prostatectomy have been included, with availability of histology as gold standard to validate intraprostatic findings and local extension. Our results suggest that the use of PET/MRI with a dual tracer approach can improve PCa staging, by providing complementary information ameliorating disease characterization.
This abstract and the presentation materials are available to members only;
a login is required.